Hadassah

Hadassah-Developed Autoimmune Disease Drug Proves Safe in Phase I Clinical Trial

Thursday, Aug 6 2015

A drug developed at the Hadassah Medical Organization to help modulate the effects of autoimmune diseases such as rheumatoid arthritis has proven safe in a Phase I clinical trial at Hadassah. Manufactured by Protalix BioTherapeutics of Carmiel, Israel, the drug, PRX-106, proved to activate T cells, which have a central role in maintaining a well-functioning immune system.

"The results are very exciting and encouraging,” reports Prof. Yaron Ilan of Hadassah’s Internal Medicine Department A and a specialist in immunology and liver disease. “PRX-106 has the potential to be an effective agent for numerous immune-mediated disorders."

This Phase I trial tested the safety and tolerability of PRX-106 in healthy volunteers. With three separate cohorts receiving different doses of the protein compound for five consecutive days, the results demonstrated that oral administration of PRX-106 is safe and well tolerated in all three doses. In addition, researchers observed that PRX-106 triggered the action of various subsets of T cells, some of which are correlated with an anti-inflammatory response.

Preclinical studies with PRX-106 proved to alleviate both immune-mediated hepatitis and colitis in a mouse model, enhancing serum levels of regulatory T-cells and significantly improving clinical arthritis parameters, such as joint inflammation, swelling, and tissue degradation.

PRX-106 uses plant cells as a natural capsule for this protein compound. Protaliz anticipates that it will initiate the next phase of clinical trials with patients at the end of the year.

Related Stories

alt_text

Thursday, Oct 17 2019

Where are we with Alzheimer’s? Hadassah Doctor Provides His Perspective

With the chance that any one of us could acquire Alzheimer’s disease doubling every five years after age 60, Prof. Tamir Ben-Hur...

READ MORE ›
alt_text

Thursday, Oct 17 2019

Three More Years: An Unprecedented Extension of Life

Gerald Lieder, age 94, passed away this month. Three years ago, his family gathered from the United States and Israel to say goodbye to him because his heart was failing.

READ MORE ›
alt_text

Thursday, Oct 17 2019

Hadassah Study Sheds Encouraging Light in Treating Liver Disease

The International Journal of Molecular Medicine has published a pre-clinical study led by Prof. Rifaat Safadi, head of the Hadassah Medical Organization’s Liver Unit...

READ MORE ›
alt_text

Thursday, Oct 17 2019

Vaginal Microbiome Transplant Proves Effective Against Bacterial Vaginosis

A new treatment developed by Hadassah Medical Organization and Weizmann Institute of Science researchers, involving a vaginal microbiome transplant...

READ MORE ›
SUPPORT HADASSAH HOSPITALS

Learn more about the Hadassah Medical Organization.

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More